Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.35 |
| ▸ | PTAFR | P25105 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14590570 | 0.85 | FDPS (0.44) | ALDH1A1ACHEMAPK3MAPK1HIF1A | |
| SCHEMBL14193805 | 0.82 | FDPS (0.41) | ALDH1A1ACHEMAPK3MAPK1HIF1A | |
| SCHEMBL14590522 | 0.81 | ALDH1A1 (0.43) | ALDH1A1ACHEMAPK3MAPK1PTAFR | |
| SCHEMBL14590599 | 0.80 | PDE4A (0.41) | ALDH1A1ACHEMAPK3MAPK1HIF1A | |
| SCHEMBL10329393 | 0.79 | HIF1A (0.39) | ALDH1A1ACHEMAPK3MAPK1HIF1A | |
| SCHEMBL10329382 | 0.79 | ACACB (0.43) | DHFRDCPS | |
| SCHEMBL14590591 | 0.77 | PDE4A (0.39) | ALDH1A1ACHEMAPK3MAPK1HIF1A | |
| SCHEMBL14590511 | 0.76 | ALDH1A1 (0.37) | ALDH1A1ACHEMAPK3MAPK1PTAFR | |
| SCHEMBL13651782 | 0.76 | ALDH1A1 (0.37) | ALDH1A1ACHEMAPK3MAPK1PTAFR | |
| SCHEMBL14223465 | 0.75 | HIF1A (0.40) | ALDH1A1ACHEMAPK3MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | OXER1, NOX1, NOX4 | ALDH1A1 276/4885DHFR 3919/4885DCPS 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.